Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In patients with type 2 diabetes and rheumatoid arthritis, retrospective analyses suggest that GLP-1 receptor agonists may provide glycemic and weight benefits comparable to those seen in the general diabetes population, without apparent increases in rheumatoid arthritis flares or complications, though these observations are based on small samples
NEWS Correction 30 June 2025 Obesity drugs made in China could power next wave of treatments Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 52 print issues and online access 196,21 per year only 3,77 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Nature 643 , 315-316 (2025) doi: Updates & Corrections Correction 30 June 2025 : An earlier version of this story misnamed the US Food and Drug Administration
This could be due to differences in pharmacokinetic profile (short- vs long-acting) and due to structural differences
Telehealth startups have jumped into the GLP-1 marketplace to sell these compounded drugs, offering easy-to-access copies at a far more affordable price
US$ 24.99
US$ 20.99
US$ 26.61
US$ 22.25
US$ 24.90
